Study of the Therapeutic Effects of Naohuan Dan and Idebenone in Treating Mild Cognitive Impairment With Kidney Deficiency and Phlegm Stasis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510220
- Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510300,China
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis in accordance with both Chinese medicine and Western medicine.
- Age between 55 and 85 years, with no gender restrictions.
- A score between 21 and 26 on the Mini-Mental State Examination (MMSE), with 1 point for primary school education.
- Willingness to participate in the study and signing of the informed consent form.
Exclusion Criteria:
- Patients with severely impaired heart, liver, kidney, or other organs functions.
- Patients with neurological diseases that affect brain function and cognitive impairment.
- Patients with severe depression or other mental illnesses.
- Patients with poor compliance or cooperation who were unable to complete the study according to the protocol.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
The control group
The control group received Idebenone orally, at a dose of 30mg per time, three times a day, after meals for 12 consecutive weeks.
|
The control group took Idebenone orally for 12 weeks.
|
|
The treatmen group
The treatment group received Naohuan Dan combined with Idebenone.
At a dose of one per day, delivered with warm water in the morning and evening, and taken orally for 12 consecutive weeks.
|
The treatment group took Naohuan Dan combined with Idebenone for treatment.
Naohuan Dan is a granular preparation taken once a day, while Idebenone is a tablet taken three times a day for a total of 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from the Mini-Mental State Examination scale (MMSE) at 12 weeks
Time Frame: The time of measurement for the scale occurred twice, with the first measurement taking place before subjects were enrolled, and the second occurring at the end of their 12-week continuous medication period. Each assessment will last for one day.
|
The MMSE scale measures various cognitive domains, including orientation (10 points), memory (3 points), attention and calculation (5 points), recall ability (3 points) and language skills (9 points).
|
The time of measurement for the scale occurred twice, with the first measurement taking place before subjects were enrolled, and the second occurring at the end of their 12-week continuous medication period. Each assessment will last for one day.
|
|
Change from the clinical efficacy at 12weeks
Time Frame: The time of measurement for the scale occurred twice, with the first measurement taking place before subjects were enrolled, and the second occurring at the end of their 12-week continuous medication period. Each assessment will last for one day.
|
The clinical efficacy was evaluated based on the MMSE scale, and the efficacy was calculated by comparing the scores before and after the therapy.
The following criteria were used to determine the efficacy: (i) Markedly effective: ≥20% improvement in MMSE score.
(ii) Effective rate: ≥12% improvement in MMSE score.
(iii) Ineffective: <12% improvement in MMSE score.
|
The time of measurement for the scale occurred twice, with the first measurement taking place before subjects were enrolled, and the second occurring at the end of their 12-week continuous medication period. Each assessment will last for one day.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from the Montreal Cognitive Assessment scale (MoCA) at 12 weeks
Time Frame: The time of measurement for the scale occurred twice, with the first measurement taking place before subjects were enrolled, and the second occurring at the end of their 12-week continuous medication period. Each assessment will last for one day.
|
The MoCA scale is a widely used screening tool for detecting mild cognitive impairment.
The total score on the MoCA scale is 30, and a score of 26 or higher is considered to indicate normal cognitive function.
|
The time of measurement for the scale occurred twice, with the first measurement taking place before subjects were enrolled, and the second occurring at the end of their 12-week continuous medication period. Each assessment will last for one day.
|
|
Change from the Activities of Daily Living scale (ADL) at 12 weeks
Time Frame: The time of measurement for the scale occurred twice, with the first measurement taking place before subjects were enrolled, and the second occurring at the end of their 12-week continuous medication period. Each assessment will last for one day.
|
The ADL scale is used to assess the participants' ability to perform daily living activities.
The total score on the ADL scale is 100 points.
|
The time of measurement for the scale occurred twice, with the first measurement taking place before subjects were enrolled, and the second occurring at the end of their 12-week continuous medication period. Each assessment will last for one day.
|
|
Change from the Geriatric Depression scale (GDS) at 12 weeks
Time Frame: The time of measurement for the scale occurred twice, with the first measurement taking place before subjects were enrolled, and the second occurring at the end of their 12-week continuous medication period. Each assessment will last for one day.
|
The GDS scale is a self-report assessment tool used to detect and measure the severity of depression in older adults.
The total score on the GDS scale is 30 points.
|
The time of measurement for the scale occurred twice, with the first measurement taking place before subjects were enrolled, and the second occurring at the end of their 12-week continuous medication period. Each assessment will last for one day.
|
|
Change from the traditional Chinese medicine (TCM) syndrome score scale at 12 weeks
Time Frame: The time of measurement for the scale occurred twice, with the first measurement taking place before subjects were enrolled, and the second occurring at the end of their 12-week continuous medication period. Each assessment will last for one day.
|
The TCM clinical symptoms of the participants were evaluated using the TCM syndrome score scale.
This tool assesses the severity of specific TCM symptoms and divides them into four grades: none, mild, moderate, and severe, with 0, 2, 4, and 6 points (for main symptoms) or 0, 1, 2, and 3 points (for secondary symptoms), respectively.
|
The time of measurement for the scale occurred twice, with the first measurement taking place before subjects were enrolled, and the second occurring at the end of their 12-week continuous medication period. Each assessment will last for one day.
|
|
Change from the Serological indicators at 12 weeks
Time Frame: The time of measurement for the scale occurred twice, with the first measurement taking place before subjects were enrolled, and the second occurring at the end of their 12-week continuous medication period. Each assessment will last for one day.
|
Blood samples were collected from the participants before and after the therapy via cubital venipuncture.
Enzyme-linked immunosorbent assay (ELISA) was used to determine the serum levels of neuron-specific enolase (NSE), interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-α).
|
The time of measurement for the scale occurred twice, with the first measurement taking place before subjects were enrolled, and the second occurring at the end of their 12-week continuous medication period. Each assessment will last for one day.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SYSKY-2022-332-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.